Microvisk Continuous Blood Donation Study
Launched by MICROVISK TECHNOLOGIES LTD · Oct 17, 2024
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
The Microvisk Continuous Blood Donation Study is looking at how well new test strips can measure blood clotting for patients taking Warfarin and similar medications. These medications are often prescribed to help prevent strokes in people with irregular heart rhythms or those with artificial heart valves. Since everyone responds differently to these medications, it’s important to regularly check how well they are working through a blood test called PT/INR, which measures the time it takes for blood to clot. By donating blood for this study, participants will help develop and improve the testing process for better patient care.
To be eligible for this study, you need to be over 18 years old and currently using Warfarin therapy. Unfortunately, there are some reasons that might prevent someone from participating, such as being under 18, not being able to give consent, or having certain health conditions. If you join the study, your donated blood will be tested using Microvisk's new system as part of ongoing research, and you'll be contributing to advancements that could help many patients in the future. This study is conducted in partnership with Oxford University Hospital and aims to enhance the way we monitor anticoagulation therapy for patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Currently undergoing Warfarin therapy.
- • Over 18 years old
- Exclusion Criteria:
- A participant is not eligible for participation if ANY of the following criteria are met:
- • Participant is \<18 years of age
- • Participant is unable to give consent
- • Participant has been treated with Unfractionated Heparin, or Low Molecular Weight Heparin, within the last 7 days
- • Participant has, or is suspected of having, Anti-Phospholipid Syndrome (APS)
- • Participant is pregnant, or has been in the past 12 months
- • Participant is known to have HIV/AIDS, is a carrier of Hepatitis A, B or C, has had tuberculosis or a tropical disease
- • Participant is suspected of intravenous drug use
About Microvisk Technologies Ltd
Microvisk Technologies Ltd. is an innovative biotechnology company specializing in the development of advanced diagnostic solutions for point-of-care testing. With a focus on enhancing patient outcomes through rapid and accurate diagnostics, Microvisk leverages cutting-edge microfluidic technology to deliver reliable, user-friendly devices. The company's commitment to research and development drives its clinical trial initiatives, aimed at validating the efficacy and safety of its products in real-world settings. By bridging the gap between laboratory testing and bedside care, Microvisk Technologies Ltd. is poised to transform the landscape of medical diagnostics.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Oxford, Oxfordshire, United Kingdom
Patients applied
Trial Officials
Susan Shapiro
Principal Investigator
Oxford Haemophilia and Thrombosis Centre Oxford University Hospital NHS Foundation Trust
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported